Drug intelligence / Profile preview

eCas12f1

Development stage
Preclinical
Lead developer
Korea University College of Medicine
Modality
CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
Administration
Intravenous
01

Overview

eCas12f1 (enhanced Cas12f1) is an engineered, miniature CRISPR-based genome editing system derived from the Un1Cas12f1 protein. Developed by researchers at Korea University, it is approximately 2.6-fold smaller than SpCas9, which facilitates more efficient cellular delivery via size-constrained viral vectors such as adeno-associated virus (AAV). The system was optimized through a multilayered engineering approach that introduced specific protein mutations (D143R, T147R, K330R, G181R, and S426G) to strengthen nucleic acid interactions within the DNA-binding pocket and incorporated a modified sgRNA with a stable UUCG RNA hairpin to improve structural stability. eCas12f1 demonstrates robust genome editing activity comparable to larger nucleases like SpCas9 and AsCpf1 and is compatible with advanced applications including base editing (adenine and cytosine base editors) and transcriptional regulation, making it a versatile platform for next-generation therapeutic genome engineering.

Other names
enhanced Cas12f1enhanced miniature CRISPR Cas12f1
02

Targets

DNA

Beyond the preview

Go deeper on eCas12f1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on eCas12f1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call